Cleared Traditional

K970768 - HUMAN LYME IGM WESTERN BLOT KIT

K970768 is an FDA 510(k) clearance for HUMAN LYME IGM WESTERN BLOT KIT, manufactured by Cambridge Diagnostics Ireland, Ltd.. The device is a Class 2 Microbiology device with product code LSR cleared through the Traditional 510(k) pathway after a 402-day FDA review.

K970768 · Cambridge Diagnostics Ireland, Ltd. · Microbiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 1998
Decision
402d
Days
Class 2
Risk

K970768 is an FDA 510(k) clearance for the HUMAN LYME IGM WESTERN BLOT KIT. Classified as Reagent, Borrelia Serological Reagent (product code LSR), Class II - Special Controls.

Submitted by Cambridge Diagnostics Ireland, Ltd. (Galway, IE). The FDA issued a Cleared decision on April 9, 1998 after a review of 402 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.3830 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Microbiology submissions.

View all Cambridge Diagnostics Ireland, Ltd. devices

FDA 510(k) Submission Details - K970768

510(k) Number K970768 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 03, 1997
Decision Date April 09, 1998
Days to Decision 402 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Statement
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
300d slower than avg
Panel avg: 102d · This submission: 402d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

LSR Device Classification - Class 2, Special Controls

Product Code LSR Reagent, Borrelia Serological Reagent
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.3830
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Microbiology devices follow this clearance model.

Regulatory Peers - LSR Reagent, Borrelia Serological Reagent

All 83
Devices cleared under the same product code (LSR) and FDA review panel - the closest regulatory comparables to K970768.
LYME DISEASE B. BURGDORFERI GENOGROUP 1 WESTERN BLOT IGG (WB0400G)
K971006 · Mrl Diagnostics · Jun 1998
LYME DISEASE B. BURGDORFERI GENOGROUP 1 WESTERN BLOT IGM (WB0400M)
K971007 · Mrl Diagnostics · Jun 1998
LIMITED HUMAN LYME IGG WESTERN BLOT KIT (CAMBRIDGE DIAGNOSTICS IRELAND)
K970761 · Cambridge Diagnostics Ireland, Ltd. · Apr 1998
CAMBRIDGE BIOTECH HUMAN LYME IGG WESTERN BLOT (90111)
K971169 · Cambridge Biotech Corp. · Feb 1998
CAMBRIDGE BIOTECH HUMAN LYME IGM WESTERN BLOT (90112)
K971170 · Cambridge Biotech Corp. · Feb 1998
ACCURUN(TM) 130 BORRELIA BURGDORFERI IGG POSITIVE CONTROL
K974809 · Boston Biomedica, Inc. · Feb 1998